Mohammad R - Search Results

1

Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer.

Wang Z, Sengupta R, Banerjee S, Li Y, Zhang Y, Rahman KM, Aboukameel A, Mohammad R, Majumdar AP, Abbruzzese JL, Sarkar FH. Wang Z, et al. Among authors: mohammad r. Cancer Res. 2006 Aug 1;66(15):7653-60. doi: 10.1158/0008-5472.CAN-06-1019. Cancer Res. 2006. Retraction in: Cancer Res. 2018 Sep 15;78(18):5474. doi: 10.1158/0008-5472.CAN-18-1166 PMID: 16885366 Retracted.

2

A human B-cell lymphoma line with a de novo multidrug resistance phenotype.

Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, al-Katib A. Mohammad RM, et al. Cancer. 1992 Mar 15;69(6):1468-74. doi: 10.1002/1097-0142(19920315)69:6<1468::aid-cncr2820690626>3.0.co;2-8. Cancer. 1992. PMID: 1540884

3

Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL).

Mohamed AN, Mohammad RM, Koop BF, al-Katib A. Mohamed AN, et al. Among authors: mohammad rm. Cancer. 1989 Sep 1;64(5):1041-8. doi: 10.1002/1097-0142(19890901)64:5<1041::aid-cncr2820640514>3.0.co;2-c. Cancer. 1989. PMID: 2527086

4

Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.

Mohammad RM, al-Katib A, Pettit GR, Sensenbrenner LL. Mohammad RM, et al. Cancer Res. 1994 Jan 1;54(1):165-8. Cancer Res. 1994. PMID: 8261437

5

Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors.

Li Y, Mohammad RM, al-Katib A, Varterasian ML, Chen B. Li Y, et al. Among authors: mohammad rm. Leuk Res. 1997 May;21(5):391-7. doi: 10.1016/s0145-2126(96)00078-1. Leuk Res. 1997. PMID: 9225065

6

Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.

Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK, Sarkar FH. Mohammad RM, et al. Pancreas. 1998 Jan;16(1):19-25. doi: 10.1097/00006676-199801000-00004. Pancreas. 1998. PMID: 9436858

7

Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.

Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM. Mohammad RM, et al. Clin Cancer Res. 1998 Feb;4(2):445-53. Clin Cancer Res. 1998. PMID: 9516935

8

An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.

Mohammad RM, Al-Katib A, Pettit GR, Vaitkevicius VK, Joshi U, Adsay V, Majumdar AP, Sarkar FH. Mohammad RM, et al. Clin Cancer Res. 1998 Apr;4(4):887-94. Clin Cancer Res. 1998. PMID: 9563882

9

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.

Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Al-Katib AM, et al. Among authors: mohammad rm. Clin Cancer Res. 1998 May;4(5):1305-14. Clin Cancer Res. 1998. PMID: 9607591

10

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A. Mohammad RM, et al. Clin Cancer Res. 1998 May;4(5):1337-43. Clin Cancer Res. 1998. PMID: 9607595

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters